CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Exclusion Criteria

• •History of cancer within the last five years, except superficial basal or squamous cell skin cancer or cervical carcinoma in situ
• •History of alcohol abuse or dependence within the last two years
• •Liver serum transaminases (AST and/or ALT) \> 5 times the upper limit of normal; total and/or direct bilirubin \> 1.5 mg/dL, hemoglobin \< 9mg/dL; PT and PTT \> 2 times the upper limit of normal; creatinine clearance \< 30 mL/min; positive serology for HBV or HCV; absolute neutrophil count \< 1,500 cells/mm3 and a platelet count \< 100,000/mm3
• •Any significant systemic illness, unstable or severe medical condition(s) that could put the subject at risk during the study, interfere with outcome measures or affect compliance with the protocol procedures
• •Centrally active beta-blockers, anti-Parkinsonian medications, psychostimulants, antipsychotics, neuroleptics, or narcotic analgesics, long-acting benzodiazepines or barbiturates, hypertensive agents with a CNS effect, short-acting anxiolytics or sedative hypnotics more frequently than two times per week within 14 days of screening, herbal products for Alzheimer's disease, antidepressants with significant cholinergic side effects (e.g., tricyclics), initiation or change in dose of standard treatment for Alzheimer's disease
• •Other medication with significant cholinergic or anticholinergic side effects
• •Warfarin (coumadin), nonsteroidal anti-inflammatory drugs, aspirin, Prozac, or Ginkgo biloba within 14 days of surgery
• •Subjects who have received investigational agents or been exposed to investigational devices for 30 days prior to enrollment
• •Subjects with a history of receiving gene transfer products of any kind
• •Subjects who cannot undergo MRI or PET screening